Summary

for people ages 18-85 (full criteria)
at Irvine, California and other locations
study started
estimated completion

Description

Summary

A Phase 3, randomized, double-masked, vehicle-controlled trial to evaluate the safety and efficacy of ADX-102 ophthalmic solution in Subjects with non-infectious anterior-uveitis.

Official Title

A Phase 3, Randomized, Double-masked, Vehicle-controlled Trial to Evaluate the Safety and Efficacy of ADX-102 Ophthalmic Solution in Subjects With Non-infectious Anterior-uveitis.

Keywords

Non-infectious Anterior Uveitis reproxalap Uveitis Uveitis, Anterior Iridocyclitis Pharmaceutical Solutions Ophthalmic Solutions ADX-102 Ophthalmic Solution (0.5%) Vehicle of ADX-102 Ophthalmic Solution

Eligibility

You can join if…

Open to people ages 18-85

  • Male or female subjects aged ≥ 18 years and ≤ 85 years.
  • Subjects with acute non-infectious anterior uveitis with onset of symptoms within the previous 2 weeks.
  • Best corrected visual acuity (BCVA) better than or equal to 35 letters in the study eye and 65 letters in the non-study eye using ETDRS testing.

You CAN'T join if...

  • Have severe/serious ocular pathology in the study eye(s) which may preclude study completion, in the judgement of the Investigator.
  • Active intermediate or posterior uveitis in the study eye(s).
  • Previous anterior uveitis episode in the study eye ≤ 4 weeks prior to screening.
  • Have participated in another investigational device or drug study within 30 days prior to screening.
  • Participation in a prior ADX-102 study.

Locations

  • University of California, Irvine accepting new patients
    Irvine California 92697 United States
  • Retina-Vitreous Associates Medical Group accepting new patients
    Beverly Hills California 90211 United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Aldeyra Therapeutics, Inc.
ID
NCT03131154
Phase
Phase 3
Study Type
Interventional
Last Updated